Soligenix receives usan approval for "hypericin sodium" as nonproprietary name for novel active ingredient in hybryte™ and sgx302

Princeton, n.j. , april 5, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the united states adopted names (usan) council has approved the use of the nonproprietary name of "hypericin sodium" for the novel active ingredient in both hybryte™ (research name sgx301) for the treatment of cutaneous t-cell lymphoma (ctcl) and sgx302 for the treatment of mild-to-moderate psoriasis.
SNGX Ratings Summary
SNGX Quant Ranking